The global phage therapy market is experiencing unprecedented growth as antimicrobial resistance continues to escalate worldwide. With the market valued at approximately USD 1.27 billion in 2025 and projected to reach USD 1.86 billion by 2035, the industry is expanding at a compound annual growth rate (CAGR) of 3.91% during the forecast period 2026-2035. This remarkable trajectory is driven by the increasing prevalence of multidrug-resistant bacterial infections that have rendered traditional antibiotics ineffective in numerous clinical scenarios. Healthcare systems across the globe are now recognizing bacteriophages as a viable alternative therapeutic approach, capable of targeting specific pathogens without disrupting beneficial microbiota. The rising awareness among physicians and patients about the limitations of conventional antibiotics has created a fertile ground for phage therapy adoption, with more than 120,000 phage therapy applications recorded globally in 2025 across human, veterinary, and agricultural sectors.

The market landscape is characterized by significant investments in research and development, with biotechnology firms and academic institutions collaborating to advance phage-based therapeutics. Phage Therapy Market reports indicate that key players such as Armata Pharmaceuticals, BiomX, Locus Biosciences, and Adaptive Phage Therapeutics are leading the charge in clinical development. These companies are leveraging synthetic biology and CRISPR technology to engineer precision phages with enhanced bacterial targeting capabilities exceeding 92% in laboratory studies. Regulatory frameworks are also evolving to accommodate these novel therapeutics, with the FDA and EMA establishing compassionate-use programs and fast-track designations that facilitate faster market access. The convergence of technological innovation, regulatory support, and clinical demand is positioning phage therapy as a cornerstone of future infectious disease management.

Regional dynamics further underscore the market's expansion potential, with North America commanding 33.85% of global market share in 2025, driven by robust biotechnology infrastructure and substantial government funding through initiatives like BARDA and CARB-X. Europe follows closely, benefiting from the 2023 EMA guideline that harmonizes quality and clinical expectations for phage therapeutics. Meanwhile, the Asia-Pacific region is emerging as the fastest-growing geography with a 6.6% CAGR, fueled by expanding manufacturing capabilities in China, South Korea, and Japan. The diversification of applications beyond human therapeutics into veterinary medicine, agriculture, aquaculture, and food safety is broadening the market's revenue streams and ensuring sustainable long-term growth. As genomic sequencing costs decline and AI-assisted bacterial targeting platforms improve pathogen identification accuracy by 29%, the phage therapy market is poised to transform from an experimental niche into a mainstream therapeutic modality.

Q1: What is the current market size of the phage therapy industry? The phage therapy market was valued at approximately USD 1.27 billion in 2025 and is projected to reach USD 1.86 billion by 2035, growing at a CAGR of 3.91%.

Q2: Which region dominates the phage therapy market? North America holds the largest market share at 33.85% in 2025, driven by strong biotechnology infrastructure, FDA support programs, and significant government funding initiatives.

Q3: What are the primary applications of phage therapy? Phage therapy is primarily used for infectious diseases, antibacterial resistance mitigation, biofilm infections, veterinary applications, aquaculture, agriculture, and food safety preservation.